Novartis announces commencement of tender offer to acquire Tourmaline Bio

Acquisition Announcement - Novartis has initiated a tender offer to acquire all outstanding shares of Tourmaline Bio, Inc. at a price of $48 per share in cash [1] - The tender offer is part of a previously announced Merger Agreement dated September 8, 2025 [1] Offer Details - The tender offer will expire on October 27, 2025, unless extended or terminated earlier [2] - Novartis filed a tender offer statement with the SEC, detailing the terms and conditions of the offer [3] Conditions of the Offer - The obligation to purchase shares is subject to customary conditions, including regulatory approvals and the tender of a majority of shares [4] - The offer is not contingent on financing [4] Information Agents - Innisfree M&A Incorporated is acting as the information agent for the offer, while Computershare Trust Company, N.A. serves as the depositary and paying agent [5] Regulatory Filings - Tourmaline's board of directors has recommended that stockholders accept the offer and tender their shares [3] - Both Novartis and Tourmaline have filed necessary documents with the SEC, which are available for public access [6][8]